Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 42-47

  Conroy, S ^a   Newman, C ^b   Gudka, S ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Chemotherapy; Children; Leukaemia; Off label; Unlicensed

Indexed keywords

ALIMEMAZINE; AMILORIDE; ANALGESIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBOPLATIN; CHLORPHENIRAMINE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLIZINE; CYTOTOXIC AGENT; DIURETIC AGENT; ELECTROLYTE; ETOPOSIDE; GENTAMICIN; LAXATIVE; LORAZEPAM; MERCAPTOPURINE; METHOTREXATE; NYSTATIN; ONDANSETRON; RANITIDINE; SEDATIVE AGENT; TIOGUANINE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANXIETY DISORDER; ARTICLE; CANCER PATIENT; CANDIDA; CANDIDIASIS; CAREGIVER; CHILD; CHILD CARE; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG USE; HEALTH PRACTITIONER; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFANT; INSOMNIA; LICENCE; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; NAUSEA AND VOMITING; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OUTPATIENT; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINOBLASTOMA; RHABDOMYOSARCOMA; VIRUS INFECTION;

EID: 0037249993     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg031     Document Type: Article

References (28)

1. Turner S, Gill A, Nunn T, Choonara I. Use of 'off label' and unlicensed drugs in paediatric intensive care unit. Lancet 1996; 347: 549-550.
2. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: 343-345.
3. McIntyre J, Conroy S, Avery A et al. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000; 83: 498-501.
4. Conroy S, Choonara I, Impicciatore P et al. Unlicensed and off label drug use in paediatric wards in different European countries. BMJ 2000; 320: 79-82.
5. Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 1999; 80: F142-F145.
6. Laetz T, Silberman G. Reimbursement policies constrain the practice of oncology. JAMA 1991; 266: 2996-2999.
7. Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the UK. Paediat Perinatal Drug Ther 1997; 1: 52-55.
8. Association of the British Pharmaceutical Industry. ABPI Compendium of Data Sheets and Summaries of Product Characteristics 1999-2000. London: Datapharm 1999.
9. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary No 39. London: British Medical Association and Royal Pharmaceutical Society of Great Britain 2000.
10. Royal College of Paediatrics and Child Health and Neonatal and Paediatric Pharmacists Group. Medicines for Children. London: RCPCH Publications 1999.
11. Lilleyman JS, Lennard L. Non-compliance with oral chemotherapy in childhood leukaemia. BMJ 1996; 313: 1219-1220.
12. Hutto CJ, Bratton TH. Palatability and cost comparison of five liquid corticosteroid formulations. J Pediat Oncol Nurs 1999; 16: 74-77.
13. Royal Pharmaceutical Society of Great Britain. From compliance to concordance: towards shared goals on medicine taking. London: RPS 1997.
14. Valanis B, Vollmer W, Labuhn K, Glass A. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med 1997; 39: 574-580.
15. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med 1999; 41: 632-638.
16. Ballantine NE. Concern over Glaxo Wellcome discontinuations. Pharm J 2000; 265: 162-163.
17. Ballantine NE. Disagreement. Pharm J 2000; 265: 396.
18. Association of the British Pharmaceutical Industry, Department of Health. Ensuring Best Practice in the Notification of Product Discontinuations. London: Department of Health Best Practice Guidelines May 2001.
19. Alder Hey Book of Children's Doses, 6th edition. Liverpool, UK: Royal Liverpool Children's Hospital (Alder Hey) 1994.
20. Boos J. Drug trials in paediatric oncology: a multi-facetted problem. Int J Clin Pharmacol Ther 1998; 36: 613-620.
21. European Agency for the Evaluation of Medicinal Products (EAEMP). Note for Guidance on Clinical Investigation of Medicinal Products in Children. London: EAEMP 1997.
22. European Agency for the Evaluation of Medicinal Products. ICH Topic E11 Clinical Investigation of Medicinal Products in the Paediatric Population. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population (CPMP/ICH/2711/99). London: EAEMP 2000.
23. Food and Drug Administration Modernization Act. Pub. L. 105-115 Section 111 of (21 USC 355A). Rockville, MD: U.S. Food and Drug Administration 1997.
24. Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Federal Drug Register 1998; 63: 6631-6672.
25. The Pediatric Exclusivity Provision. January 2001 Status Report to Congress. Washington, DC: Department of Health and Human Services, US Food and Drug Administration 2001.
26. Kearns GL. The Pediatric Pharmacology Research Unit Network: proof of concept. Paediat Perinatal Drug Ther 1999; 3: 9-14.
27. Impicciatore P, Choonara I. Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 1999; 48: 15-18.
28. European Commission. Better Medicines for Children. Proposed regulatory actions on paediatric medicinal products. European Commission 2002. [on-line] http://pharmacos.eudra.org/F2 (9 August 2002, date last accessed).